Thelansis

 Waldenstrom macroglobulinemia (WM) is a B-cell lymphoproliferative disorder characterized by the accumulation of monoclonal cells in both the bone marrow and peripheral lymphoid tissues. WM condition is associated with producing a monoclonal protein known as serum immunoglobulin M (IgM). While the exact cause of WM remains unknown, it is believed to have immune-related factors involved, and there is a clear familial connection, as first-degree relatives of WM patients are at an increased risk of developing the disease. While specific susceptibility genes have not yet been pinpointed, susceptibility loci have been identified on chromosome 6p21.3 and 4q. In addition, approximately half of WM patients exhibit 6q deletions on their tumor cells. WM is typically diagnosed at a median age of 72 and is twice as common in men as in women. The primary clinical manifestations include hepatosplenomegaly, lymphadenopathy, constitutional symptoms, oronasal bleeding, hyperviscosity syndrome, and...

 Waldenstrom macroglobulinemia (WM) is a B-cell lymphoproliferative disorder characterized by the accumulation of monoclonal cells in both the bone marrow and peripheral lymphoid tissues. WM condition is associated with producing a monoclonal protein known as serum immunoglobulin M (IgM). While the exact cause of WM remains unknown, it is believed to have immune-related factors involved, and there is a clear familial connection, as first-degree relatives of WM patients are at an increased risk of developing the disease. While specific susceptibility genes have not yet been pinpointed, susceptibility loci have been identified on chromosome 6p21.3 and 4q. In addition, approximately half of WM patients exhibit 6q deletions on their tumor cells. WM is typically diagnosed at a median age of 72 and is twice as common in men as in women. The primary clinical manifestations include hepatosplenomegaly, lymphadenopathy, constitutional symptoms, oronasal bleeding, hyperviscosity syndrome, and...

 Waldenstrom macroglobulinemia (WM) is an indolent (slow-growing) subtype of non-Hodgkin lymphoma that affects small lymphocytes (white blood cells). WM probably begins with one or more acquired changes (mutations) to the DNA of a single B lymphocyte. Cancer causes the overproduction of a monoclonal protein called “immunoglobulin M” (IgM), which can result in a thickening of the blood known as “hyperviscosity.” This monoclonal IgM protein may lead to many symptoms, including fatigue, unexplained weight loss, enlarged lymph nodes or spleen, weakness, and unexplained bleeding. At the time of diagnosis, WM most commonly involves the blood and bone marrow; however, WM can start almost anywhere and spread to almost any part of the body, affecting the lymph nodes, liver, spleen, stomach intestines, or lungs. WM rarely involves the skin or thyroid gland. ·        WM is rare, with an incidence rate of about 6 cases per million people per year in the United S...